



Stimunity secures 2M€ from Portage to advance preclinical validation and manufacturing of its STING program

Paris, February 28, 2018 - Stimunity, the Paris-based cancer immunotherapy company focused on STING, is pleased to announce that the company has secured a 2M€ seed investment from Portage, a US/Canadian listed company that supports the discovery and development of pharmaceutical and biotech products through clinical proof-of-concept.

This seed investment will help the company to complete the preclinical package and advance the development of the manufacturing of STING-activating virus-like particles to pharmaceutical grade. Dr. Ian B. Walters, board member of Portage, will be chairing Stimunity's Board of Directors. "We are very excited by our collaboration with Portage; it not only brings significant investment to the table, but also provides strong expertise in immuno-oncology and clinical development. We are happy to welcome Ian onto our board" says Sylvain Carlioz, co-founder and CEO of Stimunity.

Portage is actively investing in promising companies that have the potential to be a game changer in the immunotherapy field. "The collaboration between Stimunity and Portage opens another chapter for Portage, providing the company with a program advancing into human testing. Stimunity's technology has the potential to stimulate the tumor microenvironment and promote an immune response in a safer and more potent fashion than other STING agonists. We believe these properties will enable Stimunity's STING agonists to become an important adjuvant to checkpoint inhibitors in non-immunogenic tumor types" says Greg Bailey, Chairman of Portage.

Today, immunotherapy in oncology is a breakthrough, providing long-term survival for patients with advanced/metastatic cancer but only effective on less than 50% of patients. Non-responding patients fail to mount a strong immune response against their tumors, and there is a major need for new treatments that activate such response.

The lead program is now at the early phase of preclinical stage validation and will need an additional 2 years to get into the clinic. Nicolas Manel, co-founder, inventor, and Chairman of the Scientific Advisory Board is very confident: "Early *in vivo* data shows that our approach synergizes with immune checkpoint therapies and leads to a potent therapeutic effect on distant tumors which is what most of patients need".



About Portage



Portage is engaged in supporting the discovery and development of pharmaceutical and biotech products through clinical “proof of concept” with a focus on areas of unmet clinical need. Following proof of concept, Portage will seek to sell or license these products to large pharmaceutical or biotechnology companies for further development and commercialization. Portage has an interest in novel targeted therapies, stem cell therapies, and new indications for older marketed products that have been found to have novel patentable characteristics that bring new value to patients.

For further information, contact Kam Shah, Chief Financial Officer, by telephone at (416) 929- 1806, by email at ks@portagebiotech.com or through our website, www.portagebiotech.com.

About Stimunity



Stimunity is an early-stage research and development company focused on the development of STING agonists in cancer. The technology, licensed from Institut Curie, Inserm, and University of Oxford, is based on a unique biologic approach which combines the endogenous STING activator encapsulated in a Virus-Like Particle (VLP). Stimunity’s drug is best-in-class, and activates the innate immune system, enhances T-cell response against tumor cells, with a low immunogenicity.

More information at <http://stimunity.com> or contact@stimunity.com.